Nestlé Health Science has reached a non-binding memorandum of understanding with Seres Therapeutics for the acquisition of certain assets associated with Vowst (fecal microbiota spores, live-brpk) capsules. This agreement will replace any previous agreements between Nestlé and Seres related to Vowst. The transaction is expected to be completed once definitive agreements are reached, shareholder approval is obtained, and other customary conditions are met.
Nestlé Health Science has been leading the commercialization efforts for Vowst since it was launched in June 2023 in the United States. The agreement will grant Nestlé Health Science full control over the future development, commercialization, and manufacturing of Vowst both in the U.S. and globally.
Vowst is the first FDA-approved orally administered microbiota-based therapeutic specifically designed to prevent recurrence of Clostridioides difficile infection in adults following antibacterial treatment for recurrent CDI. President of medical nutrition and pharma at Nestlé Health Science, Moreno Perugini, expressed satisfaction with the success of Vowst since its introduction to patients in June the previous year. He highlighted the productive collaboration with Seres during the development and FDA approval of Vowst, emphasizing the importance of continuing to provide this medication to patients.
Perugini emphasized how Vowst aligns with Nestlé Health Science’s expertise in gastrointestinal disorders and their commitment to meeting significant unmet needs in the market. Once completed, Nestlé Health Science will have complete ownership over the development, commercialization, and manufacturing of Vowst, ensuring the continued growth of sales and the benefit of many more patients from this innovative medication.
The acquisition is expected to strengthen Nestlé Health Science’s position as a leader in gastrointestinal disorders while also providing Seres Therapeutics with additional resources to focus on research and development efforts.
Nestlé Health Science’s acquisition of certain assets associated with Vowst from Seres Therapeutics marks a significant milestone in their efforts to provide innovative solutions for gastrointestinal disorders.
The finalization of this transaction is pending negotiations on definitive agreements, shareholder approval, and fulfillment of other customary conditions.
